high-purity/sterile Ropivacaine mesylate (84057-95-4)

Name:Ropivacaine mesylate
Cas No:84057-95-4
MF:C17H26N2O
Use:anaesthetic
Appearance:white powder
NAME:Ropivacaine mesylate

GENERAL INTRODUCTION:

Indications
Ropivacaine is indicated for local anaesthesia including infiltration,
Ropivacaine is often co-administered with fentanyl for epidural analgesia, for example in pregnant women during labour.
Contraindications
Ropivacaine is contraindicated for IV regional anaesthesia (IVRA). However, new data suggested that both Ropivacaine (1.2-1.8mg/kg in 40ml) and levobupivacaine (40ml of 0.125% solution) can be used, because they have less cardiovascular and central nervous system toxicity than racemic bupivacaine (Basic of Anesthesia, Robert Stoelting, page 289).
Adverse effects
Adverse drug reactions (ADRs) are rare when it is administered correctly. Most ADRs relate to administration technique (resulting in systemic exposure) or pharmacological effects of anesthesia, however allergic reactions can rarely occur.
Systemic exposure to excessive quantities of ropivacaine mainly result in central nervous system (CNS) andcardiovascular effects – CNS effects usually occur at lower blood plasma concentrations and additional cardiovascular effects present at higher concentrations, though cardiovascular collapse may also occur with low concentrations. CNS effects may include CNS excitation (nervousness, tingling around the mouth, tinnitus, tremor, dizziness, blurred vision, seizures) followed by depression (drowsiness, loss of consciousness, respiratory depression and apnea). Cardiovascular effects include hypotension, bradycardia, arrhythmias, and/or cardiac arrest– some of which may be due to hypoxemia secondary to respiratory depression.
nerve block,
epidural and intrathecal anaesthesia in adults and children over 12 years. It is also indicated for peripheral nerve block and caudal epidural in children 1–12 years for surgical pain. It is also sometimes used for infiltration anaesthesia for surgical pain in children.